FORT LEE, N.J.--(BUSINESS WIRE)--Aug. 29, 2006--Neurologix, Inc. (OTCBB: NRGX), a biotech company engaged in the development of innovative gene therapies for the brain and central nervous system, today announced that the Board of Directors had increased its size to nine directors and appointed Cornelius E. Golding, age 58, as a Class II director. Mr. Golding will serve on the Company’s Audit Committee.
